Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)
- Institution
- LSU PENNINGTON BIOMEDICAL RESEARCH CTR, LA
- Principal investigator
- Robert Lee Newton
- Funding
- $705K
- Duration
- 2019–2025
Moonbase score
Still being scored
Abstract
Abstract Alzheimer's Disease is steadily growing in prevelance, with a devastating public health impact. The prevelance of Alzheimer's Disease is higher in African Americans compared to white Americans, thereby constituting a health disparity. Interventions that prevent Alzheimer's Disease or change the course of cognitive decline associated with Alzheimer's Disease are needed. Most older adults do not achieve the recommended levels of physical activity, and this includes African Americans. Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. Therefore our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. We evaluate exercise benefits among elderly African Americans, who are understudied and in whom the natural course of neurodegeneration, exercise effects in neuroprotection and neurodegeneration, and resulting clinical phenotypes may differ. A large body of exisiting data suggests that exercise improves cardiovascular and cerebrovascular functioning, and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. At the same time, chronic exercise has been shown to decrease central levels of inflammatory markers and increase central levels of neurotrophic factors, which in turn promote protection against Alzheimer's Disease neurodegeneration pathways via a variety of mechanisms. While physical activity interventions have been shown to have positive effects on these factors and on resultant cognitive functioning in older adults, nearly all interventions have had a negligible representation of African Americans. Prior dara suggests that African Americans enter their elderly years against a backdrop of different lifespan exposures to a variety of factors relevant to neuroprotection and neurodegeneration, including cardiovascular risk, exercise, diet, and education. In addition, prior data suggests that the key genetic risk factor for Alzheimer's Diease (APOE) may have differing consequences for Alzheimer's Diease risk among African Americans, and other genetic differences have the potential to influence the brain benefits of physical activity in this community. We will utilize a randomized clinical trial to address these questions. Participants will be randomized into a physical promotion intervention or a healthy aging information group for 52 weeks. All participants will be of normal cognitive function. We will assess cognitive function, brain structure and function, circulating hormones, objectively measured physical activity, cardiorespiratory fitness, and telomere length. Our study will take the first step toward understanding whether the hypothesized benefits of exercise for the brain carry over to elderly African Americans.
Research team
- Owen T. CarmichaelPI
- Robert Lee NewtonPI
LOADING MOONBASE SCORE
Questions for LSU PENNINGTON BIOMEDICAL RESEARCH CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Illinois at ChicagoNot yet scored
Early Life Cardiovascular Disease Risk Factors, Epigenetic Age Acceleration, and Alzheimer's Disease Related Brain Health
Lydia Bazzano · $694K · 2022–2027
- NIH · Tulane University of LouisianaNot yet scored
I3C DECADE: Disparities and Equity in Childhood Cardiovascular Exposures and Alzheimer's Dementia
Lydia Bazzano · $2.9M · 2022–2027
- NIH · Lsu Pennington Biomedical Research CtrNot yet scored
The Louisiana Center for Advancing Uplifting Scientists Careers in Health, Nutrition, Obesity, and Diabetes Research (LAUNCHED)
Peter Todd Katzmarzyk · $599K · 2022–2027